Overview
| 别名 | Granzyme B; C11; CTLA-1; Cathepsin G-like 1; CTSGL1; Cytotoxic T-lymphocyte proteinase 2; Lymphocyte protease; Fragmentin-2; Granzyme-2; Human lymphocyte protein; HLP; SECT; T-cell serine protease 1-3E |
| 基因名 | Granzyme B |
| UniProt ID | P10144 |
| 反应种属 | Human |
| 应用 | IHC-P |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG1 |
| 克隆号 | 6Q2-E8-T1 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 27 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | IHC-1:200 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | Granzyme B (GZMB) is a serine protease encoded by the GZMB gene on chromosome 14q.11.2, playing a crucial role in the immune response by inducing apoptosis in virus-infected and tumor cells. It is secreted by cytotoxic lymphocytes and enters target cells via the pore-forming protein perforin, activating caspases that trigger apoptotic pathways. GZMB has a unique substrate specificity, cleaving proteins involved in various cellular processes, including inflammation and extracellular matrix remodeling. Elevated levels of GZMB have been associated with several diseases, including cancer, where it can overcome resistance to conventional therapies. Its ability to induce apoptosis makes it a potential therapeutic agent in immunotherapy for malignancies. Additionally, GZMB is implicated in inflammatory responses and tissue repair, highlighting its dual role in both promoting cell death and facilitating recovery from injury. |
检测原理